T Cell Receptor recognized Anti-Idiotypic Antibody Discovery Service

Introduction Anti-Idiotypic Antibody Detect T Cell Receptor Guarantees Published Data

Creative Biolabs provides anti-idiotypic antibody production service detecting T cell receptors. We utilize target TCR in scFv form or using a peptide designed according to the sequences of the variable domains as target to isolate anti-idiotypic antibodies from immunized phage display library. Anti-idiotypic antibodies could bind to idiotypes that were epitopes present in the variable regions of the receptors of both T and B lymphocytes, and each receptor carries a set of idiotopes that defines its unique idiotype.

Introduction

Anti-idiotypic antibodies (Anti-ID Abs) are antibodies that can recognize and specifically bind to the variable regions of antibodies. The rapid development of antibody drugs in recent years has greatly increased the demand for customized anti-idiotypic antibodies, which play a vital role in the pharmacokinetic (PK) and pharmacodynamic (PD) analysis of antibody drugs, immunogenicity analysis, etc.

Anti-Idiotypic Antibody Detect T Cell Receptor

In 95% of T cells, this consists of an α and β chain, whereas in 5% of T cells this consists of γ and δ chains. This ratio changes during ontogeny and in diseased states. So the idiotype of each V region of a single immunoglobulin molecule may be comprised of as many as 15–20 idiotopes, which can be distinguished by monoclonal anti-idiotypic antibodies or defined by a specific and unique amino acid sequence.

Schematic diagram of TCR structure. Fig.1 The structure of TCR.^{1, 3}

If variable regions of both the heavy- and light-chains contribute idiotypic determinants, the idiotype is likely to be a conformational determinant. On the other hand, individual idiotypes may be located either in the heavy- or light-chains and contained in the primary amino acid sequences of the variable regions. These idiotypes are more likely to be sequence-dependent, and linear antigenic determinants.

The hypervariable regions (also known as complementarity determining regions or CDRs) are thought to be the primary immunogenic sites within the variable region, but any part of the variable region of immunoglobulin may contribute to the structure of an idiotype. In a number of systems, the CDR3 region has been shown to be the highest contributor; however, contributions by CDR1 and CDR2 are not uncommon.

Guarantees:

• Fast delivery
• High success rate
• Modification of antibody as required
• High specificity and binding affinity

Please click here to see more custom Anti-Idiotypic Antibodies Production Services from Creative Biolabs to meet your specific requirements.

Published Data

Idiotypic/anti-idiotypic network hypothesis. Fig.2 Hypothesized idiotypic/anti-idiotypic interactions, T lymphocytes can be inhibited through anti-Id antibody binding to their T cell receptors.^{2, 3}

The idiotypic network hypothesis suggests a regulatory function for the humoral immune response, where an 'idiotypic network' of interconnected lymphocytes and antibodies governs immune tolerance. The idiotope, an antibody's antigen-binding site, doubles as an epitope for other antibodies, thus giving rise to anti-Id antibodies that mediate peripheral tolerance. Emerging evidence suggests that anti-Id antibodies may target TCR in neonatal mice to modulate early T lymphocyte repertoire development. The potential involvement of maternally-derived idiotypic/anti-idiotypic interactions in neutralizing maternal autoantibodies and influencing neonatal lymphocyte profiles may elucidate why neonates, despite circulating high levels of maternal autoantibodies, do not exhibit increased autoimmune susceptibility. This maternal influence likely contributes to the reduced participation of these autoantibodies in triggering autoimmune conditions during early life, highlighting a crucial mechanism of immune tolerance and repertoire shaping in neonates.

Creative Biolabs provides you with high-level anti-idiotypic antibody production services for detecting T cell receptors. We have first-class technology and rich experience to help you develop antibody drugs.

References

Sun, Yimo, et al. "Evolution of CD8+ T cell receptor (TCR) engineered therapies for the treatment of cancer." Cells 10.9 (2021): 2379.
Strachan, Erin, Xavier Clemente-Casares, and Sue Tsai. "Maternal provisions in type 1 diabetes: Evidence for both protective & pathogenic potential." Frontiers in Immunology 14 (2023): 1146082.
Distributed under Open Access license CC BY 4.0, without modification.

All listed services and products are For Research Use Only. Do Not use in any diagnostic or therapeutic applications.

	USA: Europe: Germany:
	Call us at: USA: UK: Germany:
	Fax:
	Email: